GeneDx Reports Strong 2025 Growth but Faces Rising Costs
Event summary
- GeneDx reported $427.5 million in full-year 2025 revenue, up 41% YoY.
- Exome and genome test volume grew 30.5% YoY to 97,271 tests.
- Adjusted gross margin expanded to 71%, up from 65% in 2024.
- Operating expenses increased 39% YoY to $263 million.
- Company reaffirmed 2026 guidance with expected revenue of $540-$555 million.
The big picture
GeneDx is capitalizing on the growing demand for genomic testing, particularly in rare disease diagnosis. The company's strategic expansions into new markets and partnerships with organizations like Komodo Health position it to maintain leadership in a competitive healthcare landscape. However, rising operating costs could pressure margins if not carefully managed.
What we're watching
- Cost Control
- Whether GeneDx can manage rising operating expenses while maintaining growth momentum.
- Market Penetration
- The pace at which GeneDx expands into underpenetrated markets like general pediatrics and prenatal diagnostics.
- Regulatory Dynamics
- How changes in payer coverage and FDA designations will impact adoption rates for GeneDx's tests.
Related topics